Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial

Open access

Abstract

BACKGROUND Sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA2a) activity is deficient in the failing heart. Correction of this abnormality by gene transfer might improve cardiac function. We aimed to investigate the clinical benefits and safety of gene therapy through infusion of adeno-associated virus 1 (AAV1)/SERCA2a in patients with heart failure and reduced ejection fraction. METHODS We did this randomised, multinational, double-blind, placebo-controlled, phase 2b trial at 67 clinical centres and hospitals in the USA, Europe, and Israel. High-risk ambulatory patients with New York Heart Association class II-IV symptoms of heart failure and a left ventricular ejection fraction of 0·35 or less due to an ischaemic or non-ischaemic cause were randomly assigned (1:1), via an interactive voice and web-response system, to receive a single intracoronary infusion of 1 × 10(13) DNase-resistant particles of AAV1/SERCA2a or placebo. Randomisation was stratified by country and by 6 min walk test distance. All patients, physicians, and outcome assessors were masked to treatment assignment. The primary efficacy endpoint was time to recurrent events, defined as hospital admission because of heart failure or ambulatory treatment for worsening heart failure. Primary efficacy endpoint analyses and safety analyses were done by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01643330. FINDINGS Between July 9, 2012, and Feb 5, 2014, we randomly as…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)00082-9

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 525

Metadata

Authors
Greenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Desai, A. S., Barnard, D., Bouchard, A., Jaski, B., Lyon, A. R., Pogoda, J. M., Rudy, J. J., & Zsebo, K. M.
Affiliations
  • University of California San Diego (US)
  • Stony Brook University (US)
  • Duke University (US)
  • Wroclaw Medical University (PL)
  • University of Groningen (NL)
  • Brigham and Women's Hospital (US)
  • Sharp Memorial Hospital (US)
  • Royal Brompton Hospital (GB)
  • Celladon Corporation (United States) (US)
  • Santa Barbara Museum of Natural History (US)
Corresponding author
Greenberg, Barry
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-03
Volume
387
Issue
10024
Pages
1178-1186
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2271175958
Cited by
525
References
24
Citations by year
2026: 49 · 2025: 54 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 55 · 2020: 45 · 2019: 42 · 2018: 52 · 2017: 57 · 2016: 35
FWCI
50.03
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • Celladon Corporation
  • National Institute for Health and Care Research
  • British Heart Foundation (FS/11/67/28954)
  • National Institutes of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
SERCA2a, gene therapy, heart failure with reduced ejection fraction, intracoronary infusion, calcium handling, cardiac function
MeSH terms
Dependovirus, Aged, Calcium, Double-Blind Method, Female, Genetic Vectors, Heart Failure, Humans, Male, Middle Aged, Recurrence, Genetic Therapy, Up-Regulation, Treatment Outcome, Kaplan-Meier Estimate, Sarcoplasmic Reticulum Calcium-Transporting ATPases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)00082-9
The paper
Greenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Desai, A. S., Barnard, D., Bouchard, A., Jaski, B., Lyon, A. R., Pogoda, J. M., Rudy, J. J., & Zsebo, K. M. (2016). Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)00082-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.